DURECT Corp represents values of innovation, dedication, and quality. With a strong corporate philosophy focused on improving patient outcomes, DURECT Corp strives to develop and deliver advanced pharmaceutical products and therapeutics. The company aims to address unmet medical needs by leveraging its expertise in drug delivery technologies. DURECT Corp emphasizes a patient-centric approach, fostering collaboration with healthcare professionals and leveraging partnerships to accelerate the development and commercialization of its products. By providing novel solutions and demonstrating a commitment to improving healthcare, DURECT Corp establishes itself as a leading player in the pharmaceutical industry.

DURECT Corp is primarily present in the United States, focusing on the development and commercialization of innovative pharmaceutical products.

DURECT Corp has achieved several significant milestones. The company successfully developed and gained regulatory approval for its proprietary drug delivery platform, the DURIN technology. This platform allows for controlled and sustained release of drugs, improving therapeutic outcomes. DURECT Corp also received FDA approval for its postoperative pain relief medication, Posimir, providing patients with a non-opioid alternative for pain management. Additionally, the company entered into strategic partnerships with pharmaceutical giants such as Gilead Sciences and Indivior, benefiting from their expertise and expanding its market reach. These achievements reflect DURECT Corp's commitment to innovation and its potential for future growth.

DURECT Corp is a pharmaceutical company with a rich history and a strong background. Founded in 1998, the company is focused on developing innovative therapies that help improve the lives of patients. DURECT Corp has consistently demonstrated its commitment to research and development, aiming to address unmet medical needs. With a diverse portfolio of drug delivery technologies and proprietary formulations, the company has been successful in creating unique solutions in the pharmaceutical industry. DURECT Corp continues to collaborate with partners and regulatory agencies to bring its products to market, establishing a solid reputation for its dedication to advancing healthcare.

The main competitors of DURECT Corp in the market include pharmaceutical companies such as Pfizer, Merck & Co., Johnson & Johnson, and Novartis. These established industry leaders consistently compete with DURECT Corp in various segments of the pharmaceutical market. Despite facing competition, DURECT Corp strives to differentiate itself through its innovative drug delivery technologies and collaboration with other pharmaceutical companies. Through their unique product offerings and strategic partnerships, DURECT Corp aims to establish a significant presence and gain a competitive edge in the challenging pharmaceutical market landscape.

DURECT Corp is primarily active in the pharmaceutical and healthcare industries.

The business model of DURECT Corp revolves around the development and commercialization of pharmaceutical products. DURECT Corp specializes in developing drug delivery technologies and formulation solutions. The company focuses on creating pharmaceutical products that enhance the therapeutic benefits, provide patient convenience, and improve safety profiles. DURECT Corp collaborates with pharmaceutical companies to develop and market their products, utilizing its proprietary technologies and expertise. By leveraging its innovative drug delivery technologies, DURECT Corp aims to improve the efficacy, safety, and compliance of various medications, thereby addressing unmet medical needs.

DURECT KGV ir -1,10.

DURECT KUV ir 2,85.

AlleAktien kvalitātes vērtējums DURECT ir 4/10.

gaidāmā DURECT apgrozījums ir 10,32 milj. USD.

gaidāmā DURECT peļņa ir -26,81 milj. USD.

DURECT Corp is an innovative biopharmaceutical company specializing in the development and manufacture of drug delivery systems and novel therapies. The company was founded in 1998 and is headquartered in Cupertino, California. DURECT Corp has two business segments: DURECT Pharmaceutical and LACTEL Absorbable Polymers. DURECT Pharmaceutical develops innovative drug delivery platforms that revolutionize the way medications can be administered. This includes depot formulations that allow for sustained release of medications over a longer period, enabling better patient compliance and therapy. LACTEL Absorbable Polymers is a leading developer of resorbable polymers used in medical devices, wound care, and pharmaceutical development. Regarding DURECT Corp's product offerings, there are several important medications that the company has developed. The medication POSIMIR is a depot formulation of bupivacaine used for pain relief after surgeries. It is approved in the United States and Canada and has the potential to revolutionize postoperative pain management. Another important medication from DURECT Corp is REMOXY, a depot formulation of oxycodone for the treatment of chronic pain. REMOXY is approved in the United States. DURECT Corp also has other medications in various stages of development, including DUR-928 for the treatment of liver and kidney diseases, POSIMIR-PHASE 3 for knee pain treatment, and DUR-100B, a new drug delivery system through the nasal mucosa. DURECT Corp's business model is based on collaboration with leading pharmaceutical companies worldwide to develop innovative drug delivery platforms and novel therapies. The company has partnerships with major pharmaceutical companies such as Pfizer, Sandoz, and Gilead to jointly develop and distribute medications. Through these partnerships, DURECT Corp can bring its medications to market more effectively and quickly, and expand its business. DURECT Corp also has a strong focus on research and development to develop innovative technologies and strategies to improve the way medications are administered. The company has acquired a wide range of patents and intellectual property to protect its developments and maintain market leadership in this field. Overall, DURECT Corp has built a strong business model that focuses on the development of innovative drug delivery systems and novel therapies. Through partnerships with leading pharmaceutical companies and a strong focus on research and development, the company has the potential to become a major player in the biopharmaceutical industry and enable better treatment and care for patients.

DURECT izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt DURECT vai uzņēmums nedod dividendes.

DURECT ISIN ir US2666051048.

DURECT WKN ir 564868.

DURECT simbols ir DRRX.

Pēdējo 12 mēnešu laikā DURECT maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos DURECT plāno maksāt dividendes 0 USD apmērā.

DURECT pašreizējā dividendu rentabilitāte ir .

DURECT maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

DURECT pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

DURECT tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu DURECT apmērā 0 USD, kas tika izmaksāta 17.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.08.2024..

Pēdējās dividendes izmaksa notika 17.08.2024..

Gadā 2023, DURECT izmaksāja 0 USD dividendes.

DURECT dividendes tiek izmaksātas USD.